An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
about
Pathogenesis of systemic sclerosis-current concept and emerging treatments.Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target.Autotaxin in Pathophysiology and Pulmonary Fibrosis.
P2860
An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
An Autotaxin/Lysophosphatidic ...... p Drives Scleroderma Fibrosis.
@en
An Autotaxin/Lysophosphatidic ...... p Drives Scleroderma Fibrosis.
@nl
type
label
An Autotaxin/Lysophosphatidic ...... p Drives Scleroderma Fibrosis.
@en
An Autotaxin/Lysophosphatidic ...... p Drives Scleroderma Fibrosis.
@nl
prefLabel
An Autotaxin/Lysophosphatidic ...... p Drives Scleroderma Fibrosis.
@en
An Autotaxin/Lysophosphatidic ...... p Drives Scleroderma Fibrosis.
@nl
P2093
P2860
P356
P1476
An Autotaxin/Lysophosphatidic ...... p Drives Scleroderma Fibrosis.
@en
P2093
Andrew M Tager
Clemens K Probst
Flavia V Castelino
Gretchen Bain
Katharine E Black
Lance Goulet
Leaya George
Robert Lafyatis
Veronica A Pace
P2860
P304
P356
10.1002/ART.39797
P577
2016-07-07T00:00:00Z